Abstract
The increase in obesity prevalence is problematic as this condition is associated with health complications such as diabetes and cardiovascular diseases, more particularly when the excess body fat is stored in the deep abdominal region. The mainstay of therapy consists of behavior modification related to obesity such as overeating and physical inactivity. When these lifestyle modifying attempts fail, the use of anti-obesity drugs is warranted. Drug treatment is often indicated but is somewhat limited by the minimal number of well tolerated drugs that have proven to have long-term efficacy in maintaining body weight loss. The currently available drugs, sibutramine and orlistat, appear modestly effective in promoting weight loss. Ongoing studies continue to evaluate other drug treatments that may result in body weight reduction through a number of different mechanisms. Thus, the aim of this review is to present an overview of the current drugs available (particularly sibutramine and orlistat) as well as potential future candidates, and the impact of these agents on obesity and cardiovascular physiology. Furthermore, the therapeutic paradox of sibutramine in preventing obesity will be discussed as well as the beneficial impact of physical exercise on cardiac economy.
Keywords: pharmacotherapy, overweight, sibutramine, orlistat, drugs, fat, heart rate, blood pressure
Current Vascular Pharmacology
Title: Obesity and Cardiovascular Physiology: Impact of some Pharmacological Agents
Volume: 3 Issue: 2
Author(s): Jean-Philippe Chaput, Sonia Berube-Parent and Angelo Tremblay
Affiliation:
Keywords: pharmacotherapy, overweight, sibutramine, orlistat, drugs, fat, heart rate, blood pressure
Abstract: The increase in obesity prevalence is problematic as this condition is associated with health complications such as diabetes and cardiovascular diseases, more particularly when the excess body fat is stored in the deep abdominal region. The mainstay of therapy consists of behavior modification related to obesity such as overeating and physical inactivity. When these lifestyle modifying attempts fail, the use of anti-obesity drugs is warranted. Drug treatment is often indicated but is somewhat limited by the minimal number of well tolerated drugs that have proven to have long-term efficacy in maintaining body weight loss. The currently available drugs, sibutramine and orlistat, appear modestly effective in promoting weight loss. Ongoing studies continue to evaluate other drug treatments that may result in body weight reduction through a number of different mechanisms. Thus, the aim of this review is to present an overview of the current drugs available (particularly sibutramine and orlistat) as well as potential future candidates, and the impact of these agents on obesity and cardiovascular physiology. Furthermore, the therapeutic paradox of sibutramine in preventing obesity will be discussed as well as the beneficial impact of physical exercise on cardiac economy.
Export Options
About this article
Cite this article as:
Chaput Jean-Philippe, Berube-Parent Sonia and Tremblay Angelo, Obesity and Cardiovascular Physiology: Impact of some Pharmacological Agents, Current Vascular Pharmacology 2005; 3 (2) . https://dx.doi.org/10.2174/1570161053586886
DOI https://dx.doi.org/10.2174/1570161053586886 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Current Drug Targets A Series of Novel Neuroprotective Blood Brain Barrier Penetrating Flavonoid Drugs to Treat Acute Ischemic Stroke
Current Pharmaceutical Design Direct and Indirect Measurement of Temporal Horn Volume and Temporal Horn Index and its Neuropsychological Correlation in Mild Cognitive Impaired and Alzheimer Diseased Patients
Current Medical Imaging Glucocorticoids and the Cardiovascular System: State of the Art
Current Pharmaceutical Design The Fetal Cardiac Function
Current Cardiology Reviews Prolonged Perfusion Predicts Recurrent Ischemic Stroke but not Transient Ischemic Attack in Patients with Symptomatic Intracranial Stenosis
Current Neurovascular Research Alterations of the Kidney Cortex Proteome in Response to Exercise Training in Normoglycemic and Hyperglycemic Conditions
Current Topics in Medicinal Chemistry Antihyperlipidemic and Antiobesity Potential of <i>Aquilaria agallocha</i> and <i>Borago officinalis</i> in Fixed-Dose Combination; A Contingent Probe with Atorvastatin and Orlistat
Current Bioactive Compounds Commentary : Hypothesis Focused Ultrasound and NXY-059 in Experimental Cerebral Ischemia: A New Therapeutic Opportunity?
CNS & Neurological Disorders - Drug Targets Statin Therapy for Native and Peri-Interventional Coronary Heart Disease
Current Molecular Medicine Meet the Editorial Board
Current Vascular Pharmacology Chymase as an Important Target for Preventing Complications of Metabolic Syndrome
Current Medicinal Chemistry Clinical Pharmacology of Frequently Used Intravenous Drugs During Bariatric Surgery in Adolescents
Current Pharmaceutical Design Impact of Clinical Audit on Adherence to the Guidelines Directed Medical Therapy in Patients Admitted with Heart Failure
Current Drug Safety Analogy of Cardiac and Renal Complications in Essential Hypertension and Aged SHR or L-NAME/SHR
Medicinal Chemistry Energy Remodeling, Mitochondrial Disorder and Heart Failure
Current Pharmaceutical Design Beneficiary and Adverse Effects of Phytoestrogens: A Potential Constituent of Plant-based Diet
Current Pharmaceutical Design HIF Prolyl 4-Hydroxylases and their Potential as Drug Targets
Current Pharmaceutical Design Novel Antidepressant Drugs, Arterial Hypertension and Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Is Atorvastatin Superior to Other Statins? Analysis of the Clinical Trials with Atorvastatin Having Cardiovascular Endpoints
Reviews on Recent Clinical Trials